Literature DB >> 18835669

Synchronisation of ovarian follicular waves in the dromedary camel (Camelus dromedarius).

J A Skidmore1, G P Adams, M Billah.   

Abstract

This study was designed to compare the efficacy of various treatments intended to synchronise follicular wave cycles in dromedary camels by removing the existing follicle of unknown size and replacing it with a follicle capable of ovulating at a known time. Camels were randomly assigned to one of five groups and treated with either (1) 5mg oestradiol benzoate (i.m.) and 100mg progesterone (i.m.; E/P, n=15), (2) 20 icrog GnRH analogue, buserelin (i.m.; GnRH, n=15), (3) 20 microg buserelin (i.m.) on Day 0 (T=0) and 500 microg prostaglandin on Day T+7 (GnRH/PG n=15), (4) transvaginal ultrasound-guided follicle ablation of all follicles > or =0.5 cm (ABL, n=15) or (5) 5 ml saline (i.m; Controls n=15). All camels were subsequently injected with 20 microg buserelin 14 days after the first treatment was given. The ovarian response was monitored daily by transrectal ultrasonography and the intervals from treatment to follicular wave emergence and also the day on which the new dominant follicle reached 1.3 cm was recorded. Amongst the treatment groups the mean interval from treatment to new follicle wave emergence and treatment to time taken for the new dominant follicle to reach 1.3 cm in diameter was shortest in the ABL group (2.3+/-0.5 days and 8.8+/-1.1 days respectively, P=0.044) and longest in the E/P group (6.4+/-0.8 days and 12.2+/-1.0 days respectively, P<0.001) whereas the GnRH and GnRH/PG groups were intermediate (3.0+/-0.5 days and 11.1+/-0.8 days GnRH; and 4.5+/-0.5 days and 10.7+/-0.7 days GnRH/PG). A total of 11/15 camels in both the GnRH and GnRH/PG groups had dominant follicles between 1.3 and 1.9 cm 14 days post treatment, of which 21 of the 22 follicles ovulated after GnRH injection on T+14. The ABL, E/P and control groups however, showed greater variability in follicle size with less camels having dominant follicles between 1.3 and 1.9 cm than the GnRH and GnRH/PG groups and more in the > or =2.0 cm or follicle regressing groups, therefore fewer of these camels ovulated (ABL n=7; E/P n=9; Control n=6) after GnRH injection on Day T+14. In conclusion, two GnRH injections 14 days apart or two GnRH injections 14 days apart and PG on Day 7 after the first GnRH were the most effective methods to synchronise ovulation rate in dromedary camels at a fixed time interval of 14 days after treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835669     DOI: 10.1016/j.anireprosci.2008.08.024

Source DB:  PubMed          Journal:  Anim Reprod Sci        ISSN: 0378-4320            Impact factor:   2.145


  5 in total

1.  Ovarian hormones and antioxidant biomarkers in dromedary camels synchronized with new and re-used controlled intravaginal drug release (CIDR)/GPG (Ovsynch) program during breeding season.

Authors:  Amal M Abo El-Maaty; Ragab H Mohamed; Amal R Abd El Hameed; Heba F Hozyen; Amal H Ali
Journal:  Trop Anim Health Prod       Date:  2019-03-01       Impact factor: 1.559

2.  Oestradiol-17beta plasma concentrations after intramuscular injection of oestradiol benzoate or oestradiol cypionate in llamas (Lama glama).

Authors:  María V Cavilla; Carolina P Bianchi; Marcelo A Aba
Journal:  Acta Vet Scand       Date:  2010-02-11       Impact factor: 1.695

3.  Effect of exogenous progesterone treatment on ovarian steroid hormones and oxidant and antioxidant biomarkers during peak and low breeding seasons in dromedary she-camel.

Authors:  Amal M Abo El-Maaty; Ragab H Mohamed; Heba F Hozyen; Adel M El-Kattan; Mona A Mahmoud; Amal H Ali
Journal:  Vet World       Date:  2019-04-17

4.  Natural and controlled ovulation in South American camelids.

Authors:  Gregg P Adams; Marcelo H Ratto; Rodrigo A Carrasco
Journal:  Anim Reprod       Date:  2018-08-03       Impact factor: 1.810

5.  Echocardiography of the normal camel (Camelus dromedaries) heart: technique and cardiac dimensions.

Authors:  Mohamed Tharwat; Fahd Al-Sobayil; Ahmed Ali; Sébastien Buczinski
Journal:  BMC Vet Res       Date:  2012-08-03       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.